周二盘中，生物制药公司因塞特医疗（Incyte）股价大涨5.19%，引起投资者关注。这一涨幅主要源于公司公布的强劲季度业绩和上调的年度销售预期。
据报道，因塞特医疗第二季度调整后每股收益达1.57美元，显著超过分析师预期的1.47美元。公司总营收为12.2亿美元，同样高于市场预期的11.5亿美元。更为重要的是，公司上调了其主打血癌治疗药物Jakafi的年销售预期，从此前的29.5亿至30亿美元上调至30亿至30.5亿美元。
因塞特医疗的首席执行官比尔·梅里表示，最新业绩使公司"很好地实现了2025年的目标"。除Jakafi外，公司的另一款药物Opzelura（用于治疗白癜风和轻中度特应性皮炎）本季度销售额也同比大增35%，达到1.645亿美元，超出市场预期。这些积极因素共同推动了投资者对公司未来增长前景的信心，进而带动股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.